Abstract
Full text links
Read article at publisher's site: https://doi.org/10.1182/blood-2010-04-261867
Read article for free, from open access legal sources, via Unpaywall: https://ashpublications.org/blood/article-pdf/116/24/5089/1461189/zh805010005089.pdf
Free after 12 months at www.bloodjournal.org
http://www.bloodjournal.org/cgi/content/full/116/24/5089
Free to read at www.bloodjournal.org
http://www.bloodjournal.org/cgi/content/abstract/116/24/5089
References
Articles referenced by this article (128)
Expression and signal transduction of the FLT3 tyrosine kinase receptor.
Acta Haematol, (3-4):218-223 1996
MED: 8677746
Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors.
Blood, (5):1661-1670 1995
MED: 7544638
The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro.
Blood, (4):1317-1325 1996
MED: 8608220
Flt3 ligand induces proliferation of quiescent human bone marrow CD34+CD38- cells and maintains progenitor cells in vitro.
Blood, (9):3563-3570 1996
MED: 8611678
Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells.
Blood, (3):881-886 2003
MED: 12676789
Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias.
Blood, (3):1089-1096 1996
MED: 8562934
Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells.
Leukemia, (2):238-248 1996
MED: 8637232
Show 10 more references (10 of 128)
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Article citations
Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect.
Front Immunol, 15:1359113, 20 Mar 2024
Cited by: 1 article | PMID: 38571944 | PMCID: PMC10987864
Review Free full text in Europe PMC
High SEC61A1 expression predicts poor outcome of acute myeloid leukemia.
Open Med (Wars), 19(1):20240944, 27 Mar 2024
Cited by: 0 articles | PMID: 38584833 | PMCID: PMC10997032
Novel Therapeutic Targets in Acute Myeloid Leukemia (AML).
Curr Oncol Rep, 26(4):409-420, 19 Mar 2024
Cited by: 2 articles | PMID: 38502417 | PMCID: PMC11021231
Review Free full text in Europe PMC
PRL2 Phosphatase Promotes Oncogenic KIT Signaling in Leukemia Cells through Modulating CBL Phosphorylation.
Mol Cancer Res, 22(1):94-103, 01 Jan 2024
Cited by: 0 articles | PMID: 37756563 | PMCID: PMC10841656
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
Blood, 142(23):1960-1971, 01 Dec 2023
Cited by: 2 articles | PMID: 37647654 | PMCID: PMC10733823
Go to all (238) article citations
Other citations
Data
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
The Future of Targeting FLT3 Activation in AML.
Curr Hematol Malig Rep, 12(3):153-167, 01 Jun 2017
Cited by: 24 articles | PMID: 28421420
Review
FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Blood, 135(17):1472-1483, 01 Apr 2020
Cited by: 38 articles | PMID: 32315388
FLT3 Inhibition in Acute Myeloid Leukemia.
Clin Lymphoma Myeloma Leuk, 20 Suppl 1:S5-S6, 01 Sep 2020
Cited by: 2 articles | PMID: 32862867
Targeting FLT3 to treat leukemia.
Expert Opin Ther Targets, 19(1):37-54, 18 Sep 2014
Cited by: 52 articles | PMID: 25231999 | PMCID: PMC4697275
Review Free full text in Europe PMC